Standardization of negative controls in diagnostic immunohistochemistry: Recommendations from the international Ad Hoc expert panel

Applied Immunohistochemistry and Molecular Morphology

Volumn 22, Issue 4, 2014, Pages 241-252

  Torlakovic, Emina E ^a,d,e   Francis, Glenn ^f,g,h   Garratt, John ^b,d,e   Gilks, Blake ^c,d,e   Hyjek, Elizabeth ^a   Ibrahim, Merdol ⁱ   Miller, Rodney ^j   Nielsen, Søren ^k,l   Petcu, Eugen B ^f   Swanson, Paul E ^m   Taylor, Clive R ⁿ   Vyberg, Mogens ^k,l  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b LIONS GATE HOSPITAL   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d Canadian Immunohistochemistry Quality Control   (Canada)

^e CAP ACP National Standards Committee for High Complexity Testing Immunohistochemistry   (Canada)

^f GRIFFITH UNIVERSITY   (Australia)

^g UNIVERSITY OF QUEENSLAND   (Australia)

^h Convenor Immunohistochemistry Anatomical Pathology Program RCPA QAP Pty Ltd ^*  (Canada)

ⁱ UNIVERSITY COLLEGE LONDON   (United Kingdom)

^j ProPath   (United States)

^k AALBORG UNIVERSITY HOSPITAL   (Denmark)

^l Nordic Immunohistochemical Quality Control (NordiQC)   (United States)

^m UNIVERSITY OF WASHINGTON   (United States)

ⁿ UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

more..

Author keywords

Canadian Immunohistochemistry Quality Control (CIQC); College of American Pathologists External Quality Assurance Proficiency Testing (CAP EQA PT); FDA classification of immunohistochemistry devices; immunohistochemistry; negative controls; Nordic immunohistochemical Quality Control (NordiQC); positive controls; quality assurance; Royal College of Pathologists of Australasia Quality Assurance Programs (RCPAQAP); standardization

Indexed keywords

CLASSIFICATION; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC PROCEDURE; EVIDENCE BASED PRACTICE; HUMAN; IMMUNOHISTOCHEMISTRY; NOMENCLATURE; NONHUMAN; PRIORITY JOURNAL; REVIEW; STANDARDIZATION; FEMALE; MALE; NEOPLASMS; PATHOLOGY; PRACTICE GUIDELINE; QUALITY CONTROL; SENSITIVITY AND SPECIFICITY; STANDARD; STANDARDS;

TUMOR MARKER;

FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; NEOPLASMS; QUALITY CONTROL; REFERENCE STANDARDS; SENSITIVITY AND SPECIFICITY; TERMINOLOGY AS TOPIC; TUMOR MARKERS, BIOLOGICAL;

EID: 84898479375     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0000000000000069     Document Type: Review

References (50)

1. Elias JM. Immunohistochemical methods. In: Dabbs D, ed. Immunohistopathology: A Practical Approach to Diagnosis. 2nd ed. Chicago, IL: ASCP Press; 2003:1-110.
2. Taylor CR, Shi S-R, Barr NJ, et al. Techniques of immunohistochemistry: principles, pitfalls, and standardization. In: Dabbs D, ed. Diagnostic Immunohistochemistry. 2nd ed. New York, NY: Churchill Livingstone Elsevier; 2006:1-42.
3. Taylor CR, Cote RJ. Immunomicroscopy: A Diagnostic Tool for the Surgical Pathologists. 3rd ed. Philadelphia, PA: Saunders; 2005: 26-28.
4. Nagle RB, Fitzgibbons PL. Consensual interpretive guidelines for diagnostic immunohistochemistry [letter]. Am J Surg Pathol. 2002;26:816-817.
5. O'Leary TJ. Standardization in immunohistochemistry. Appl Immunohistochem Mol Morphol. 2001;9:3-8.
6. National Committee for Clinical Laboratory Standards. Quality Assurance for Immunocytochemistry; Approved Guideline. NCCLS document MM4-AC. Wayne, PA: National Committee for Clinical Laboratory Standards; 1999.
7. Clinical and Laboratory Standards Institute. Quality Assurance for Design Control and Implementation of Immnohistochemistry Assays; Approved Guideline-2nd edition. CLSI document I/LA28-A2. Wayne, PA: CLSI; 2003.
8. Ramos-Vara JA, Kiupel M, Baszler T, et al. Suggested guidelines for immunohistochemical techniques in veterinary diagnostic laboratories. J Vet Diagn Invest. 2008;20:393-413.
9. Shi SR, Liu C, Taylor CR. Standardization of immunohistochemistry for formalin-fixed, paraffin-embedded tissue sections based on the antigen-retrieval technique: from experiments to hypothesis. J Histochem Cytochem. 2007;55:105-109.
10. Taylor CR. The total test approach to standardization of immunohistochemistry. Arch Pathol Lab Med. 2000;124:945-951.
11. Goldstein NS, Hewitt SM, Taylor CR, et al. Members of Ad-Hoc Committee on Immunohistochemistry Standardization. Recommendations for improved standardization of immunohistochemistry. Appl Immunohistochem Mol Morphol. 2007;15:124-133.
12. Hewitt SM, Robinowitz M, Bogen SA, et al. Quality Assurance for Design Control and Implementation of Immunohistochemistry Assays; Approved Guideline-2nd edition. Clinical and Laboratory Standards Institute (CLSI). CLSI document I/LA28-A2 (ISBN 1-56238-745- 6). Wayne, PA: Clinical and Laboratory Standards Institute; 2011:62-66.
13. Canadian Association of Pathologists-Association canadienne des pathologistes National Standards Committee. Torlakovic EE, Riddell R, Banerjee D, et al. Canadian Association of Pathologists- Association canadienne des pathologists National Standards Committee/Immunohistochemistry: best practice recommendations for standardization of immunohistochemistry tests. Am J Clin Pathol. 2010;133:354-365.
14. College of American Pathologists. College of American Pathologists Anatomic Pathology Checklist CAP Accreditation Program. Northfield, IL: College of American Pathologists; 2013:35-37.
15. Bussolati G, Gugliotta P, Volante M, et al. Retrieved endogenous biotin: a novel marker and a potential pitfall in diagnostic immunohistochemistry. Histopathology. 1997;31:400-407.
16. Horling L, Neuhuber WL, Raab M. Pitfalls using tyramide signal amplification (TSA) in the mouse gastrointestinal tract: endogenous streptavidin-binding sites lead to false positive staining. J Neurosci Methods. 2012;204:124-132.
17. Ramos-Vara JA. Principles and methods of immunohistochemistry. Methods Mol Biol. 2011;691:83-96.
18. Vosse BA, Seelentag W, Bachmann A, et al. Background staining of visualization systems in immunohistochemistry: comparison of the Avidin-Biotin Complex system and the EnVision+ system. Appl Immunohistochem Mol Morphol. 2007;15:103-107.
19. Miller RT, Kubier P. Blocking of endogenous avidin-binding activity in immunohistochemistry: the use of egg whites. Appl Immunohistochem. 1997;5:63-66.
20. Miller RT, Kubier P, Reynolds B, et al. Blocking of endogenous avidin-binding activity in immunohistochemistry: the use of skim milk as an economical and effective substitute for commercial biotin solutions. Appl Immunohistochem Mol Morphol. 1999;7:63-65.
21. Baas IO, van den Berg FM, Mulder JW, et al. Potential falsepositive results with antigen enhancement for immunohistochemistry of the p53 gene product in colorectal neoplasms. J Pathol. 1996;178:264-267.
22. Bussolati G, Leonardo E. Technical pitfalls potentially affecting diagnoses in immunohistochemistry. J Clin Pathol. 2008;61:1184-1192.
23. Bilbe N, Ibrahim M, Parry S, et al. Participant's in-house controls-a short survey. UK NEQAS ICC & ISH Immunocytochemistry Journal. 2013;100:2-3.
24. Raffeld M, Jaffe ES. Avidin-biotin labeling of cellular antigens in cryostat-sectioned tissue. Methods Mol Biol. 2010;588:271-279.
25. Shi SR, Cote RJ, Taylor CR. Antigen retrieval immunohistochemistry: past, present, and future. J Histochem Cytochem. 1997;45: 327-343
26. Nielsen S, Røge R, Emanuelsen L. NordiQC Run 36. Available at: http://www.nordiqc.org/Run-36-B14-H2/Assessment/assessment-B14- PR.htm. Accessed on January 13, 2013.
27. Ibrahim M, Dodson A, Barnett S, et al. Potential for false-positive staining with a rabbit monoclonal antibody to progesterone receptor (SP2): findings of the UK National External Quality Assessment Scheme for Immunocytochemistry and FISH highlight the need for correct validation of antibodies on introduction to the laboratory. Am J Clin Pathol. 2008;129:398-409.
28. Spicer SS, Spivey MA, Ito M, et al. Some ascites monoclonal antibody preparations contain contaminants that bind to selected Golgi zones or mast cells. J Histochem Cytochem. 1994;42:213-221.
29. Kliman HJ, Feinberg RF, Schwartz LB, et al. A mucin-like glycoprotein identified by MAG (mouse ascites Golgi) antibodies. Menstrual cycle-dependent localization in human endometrium. Am J Pathol. 1995;146:166-181.
30. Ma D, Baruch D, Shu Y, et al. Using protein microarray technology to screen anti-ERCC1 monoclonal antibodies for specificity and applications in pathology. BMC Biotechnol. 2012;12:88.
31. Ramos-Vara JA, Miller MA. When tissue antigens and antibodies get along: revisiting the technical aspects of immunohistochemistry-the red, brown, and blue technique. Vet Pathol. 2013;51:42-87.
32. Ward JM. Controls for immunohistochemistry: is "brown" good enough? Toxicol Pathol. 2004;32:273-274.
33. Burry RW. Specificity controls for immunocytochemical methods. J Histochem Cytochem. 2000;48:163-166.
34. Burry RW. Controls for immunocytochemistry: an update. J Histochem Cytochem. 2011;59:6-12.
35. Lorincz A, Nusser Z. specificity of immunoreactions: the importance of testing specificity in each method. J Nuerosci. 2008;28: 9083-9086.
36. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28:2784-2795.
37. Taylor CR. Quantifiable internal reference standards for immunohistochemistry; the measurement of quantity by weight. Appl Immunohistochem Mol Morph. 2006;14:253-259.
38. Taylor CR, Levenson RM. Quantification of Immunohistochemistry-issues concerning methods, utility and semiquantitative assessment. Histopathology. 2006;49:411-424.
39. Battifora H. The multitumor (sausage) tissue block: novel method for immunohistochemical antibody testing. Lab Invest. 1986;55: 244-248.
40. Battifora H, Mehta P. The checkerboard tissue block: an improved multitissue control block. Lab Invest. 1990;63:722-724.
41. Miller RT. Multitumor "sandwich" blocks in immunohistochemistry. Simplified method and preparation and practical uses. Appl Immunohistochem. 1993;1:156-159.
42. Hsu F, Nielsen TO, Alkushi A, et al. Tissue microarrays are an effective quality assurance tool for diagnostic immunohistochemistry. Mod Pathol. 2002;15:1374-1380.
43. Bogen SA, Vani K, McGraw B, et al. Experimental validation of peptide immunohistochemistry controls. Appl Immunohistochem Mol Morphol. 2009;17:239-246.
44. Torlakovic E. Controls in: Techniques, NordiQC. Available at: http://www.nordiqc.org/Techniques/Contol-sections.htm. Accessed December 12, 2013.
45. Cheung CC, Martin BR, Asa SL. Defining diagnostic tissue in the era of personalized medicine. CMAJ. 2013;185:135-139.
46. Ishikawa K, Miyamoto M, Yoshioka T, et al. Method for the validation of immunohistochemical staining using SCID mouse xenografts: expression of CD40 and CD154 in human non-small cell lung cancer. Oncol Rep. 2013;29:1315-1321.
47. Kaur P, Ward B, Saha B, et al. Human breast cancer histioid: an in vitro 3D co-culture model that mimics breast tumor tissue. J Histochem Cytochem. 2011;59:1087-1100.
48. IbrahimM, Parry S, Miller K. The Breast Hormonal ReceptorModule, Run 103. Immunocytochemistry. Available at: http://www.ukneqasicc. ucl.ac.uk/Run-103- Journal.pdf. Accessed on January 3, 2014).
49. Nielsen S. Recommended control tissue. Techniques. NordiQC. Available at: http://www.nordiqc.org/Techniques/Recommended- control-tissue.htm. Accessed on January 3, 2014).
50. Title 21-Code of Federal regulations. Ch. 1 Subchapter H - Medical Devices. Part 864 - Hematology And Pathology Devices - Subpart B-Biological Stains Sec. 864.1860 Immunohistochemistry reagents and kits. Available at: http://www.accessdata.fda.gov/scripts/cdrh/ cfdocs/cfcfr/CFRSearch.cfm?CFRPart= 864&showFR=1&subpart Node=21:8.0.1.1.18.2. Accessed February 25, 2014.